|
Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study. |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen |
|
|
Honoraria - Ipsen; Lexicon; Novartis; Pfizer |
Consulting or Advisory Role - Ipsen; Lexicon; Novartis; Pfizer |
Research Funding - Ipsen (Inst); Novartis (Inst) |
|
|
Travel, Accommodations, Expenses - Ipsen; Ipsen (I) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Eisai; Ipsen; Novartis; Roche |
|
|
Consulting or Advisory Role - Ipsen |
Speakers' Bureau - Ipsen; Merck; Novartis |
Research Funding - Ipsen; Novartis |
Travel, Accommodations, Expenses - Ipsen; Merck; Novartis; Roche |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Keocyt; Novartis |
|
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (I); Merck (I); Novartis (I) |
Travel, Accommodations, Expenses - Bayer; Ipsen |
Other Relationship - Novartis |
|
|
Speakers' Bureau - Ipsen; Novartis |
|
|
Consulting or Advisory Role - Ipsen; Novartis; Pfizer |
Research Funding - Ipsen; Novartis |
|
|
|
|
|
|
Stock and Other Ownership Interests - Ipsen |
|
|
|
Honoraria - Ipsen; Novartis |
Consulting or Advisory Role - Ipsen |
Speakers' Bureau - Ipsen; Novartis |
Research Funding - Ipsen; Novartis |
|
|
Honoraria - Ipsen; Novartis |
Consulting or Advisory Role - Ipsen; Novartis |
Speakers' Bureau - Ipsen; Novartis |